The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation

Current Medicinal Chemistry

Volumn 19, Issue 20, 2012, Pages 3337-3352

  Sgambato, A ^a   Casaluce, F ^a   Maione, P ^b   Rossi, A ^b   Rossi, E ^b   Napolitano, A ^c   Palazzolo, G ^d   Bareschino, M A ^b   Schettino, C ^b   Sacco, P C ^b   Ciadiello, F ^a   Gridelli, C ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

^c S G Moscati   (Italy)

^d Division of Medical Oncology   (Italy)

Author keywords

Acquired resistance; Advanced NSCLC; Epidermal growth factor mutation; Erlotinib; First line treatment; Fluorescence in situ hybridization; Gefitinib; Immunohistochemistry; Mutation detection; Polymerase chain reaction; Primary resistance; Targeted therapy

Indexed keywords

AFATINIB; CABOZANTINIB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; NERATINIB; PACLITAXEL; PLACEBO; PLATINUM; TIVANTINIB;

ACNE; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL DECISION MAKING; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEBRILE NEUTROPENIA; GENE DOSAGE; GENE MUTATION; HUMAN; INTERSTITIAL LUNG DISEASE; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PATIENT SELECTION; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN TOXICITY; VOMITING;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG DISCOVERY; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84863756482     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712801215973     Document Type: Review

References (115)

1. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer, 2010, 127: 2893-917
2. Brenner, H.; Gondos, A.; Arndt, V. Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J. Clin. Oncol., 2007, 25:3274-3280
3. Pfister, D.G.; Johson, D.H.; Azzoli, C.G. et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J. Clin. Oncol., 2004, 22:330-53
4. Giaccone, G.; Smit, E. Lung cancer. Cancer chemoter. Biol. Response Modif., 2003, 21:445-83
5. Salomon, D.S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 1995, 9:183-232.
6. Ciardiello, F.; Tortora, G.; EGFR antagonists in cancer treatment. N. Eng. J. Med., 2008, Mar 13; 358(11):1160-74
7. Sharma, S.V.; Bell, D.W.; Settleman, J.; Haber D.A. Epidermal growth factor receptor mutation in lung cancer. Nat. Rev. Cancer, 2007, 7:169-181
8. Yarden, Y. The EGFR family and its ligands in human cancer: signaling mechanism and therapeutic opportunities. Eur. J. Cancer, 2001, Sep;37 Suppl 4: S3-8
9. Ulrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell., 1990, 61:203-2012
10. Carpenter, G.; Cohen, S. Epidermal growth factor. J. Biol. Chem., 1990, 265:7709-7712
11. Wikstand, C.J.; Bigner, D.D. Prognostic applications of epidermal growth factor receptor and its ligand, transforming growth factor alpha. J. Natl. Cancer Inst., 1998, 90:799-800
12. Eberhard, D.A.; Giaccone, G.; Johnson, B.E.; Non-Small-Cell Lung Cancer Working Group. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J. Clin. Oncol., 2008, 26:983-94
13. Kato, Y.; Peled, N.; Wynes, M.W.; Yoshida, K.; Pardo, M.; Mascaux, C.; et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J. Thorac. Oncol., 2010, 5:1551-8
14. Hirsch, F.R.; Dziadziuszko, R.; Varella-Garcia, M.; Franklin, W.A. Gandara, D.R.; Bunn PA Jr. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. J. Thorac. Oncol., 2008, Jun;3 (6 Suppl 2):S138-42
15. Kimura, H.; Suminoe, M.; Kasahara, K.; Sone, T.; Araya, T.; Tamori, S.; et al. Evaluation of epidermal growth factor receptor mutations in serum DNA as a predictor of response to gefitinib (IRESSA). Br. J. Cancer, 2007, 97:778-84
16. Moran, T.; Paz-Ares, L.; Isla, D.; Cobo, M.; Massuti, B.; Insa, A.; et al. High correspondence between EGFR mutations in tissue and in circulating DNA from non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS). J. Clin. Oncol., 2007; 2007 ASCO Annual Meeting Proceedings Part I. Vo l 25, No. 18S (abstr 7505)
17. Bai, H.; Mao, L.; Wang, H.S.; Zhao, J.; Yang, L. An TT, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J. Clin. Oncol., 2009, 27:2653-9
18. Maheswaran, S.; Sequist, L.V.; Nagrath, S.; Ulkus, L.; Brannigan, B.; Collura, C.V.; et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med., 2008, 359:366-77
19. Woodburn, J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther., 1999, 82:241-250
20. Ranson, M.; Hammond, L.A.; Ferry, D.; et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol., 2002, 20(9):2240-2250
21. Baselga, J.; Rischin, D.; Ranson, M.; et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol., 2002, 20(21):4292-4302
22. Herbst, R.S.; Maddox, A.M.; Rothenberg, M.L.; et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol., 2002, 20(18):3815-3825
23. Nakagawa, K.; Tamura, T.; Negoro, S.; et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Annals of Oncology, 2003, 14(6):922-930
24. Giaccone, G.; González-Larriba, J.L.; van Oosterom, A.T.; et al. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Annals of Oncology, 2004, 15(5):831-838
25. Fukuoka, M.; Yano, S.; Giaccone, G.; et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol., 2003, 21(12):2237-2246
26. Kris, M.G.; Natale, R.B.; Herbst, R.S.; et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Journal of the American Medical Association, 2003, 290(16):2149-2158
27. Cohen, M.H.; Williams, G.A.; Sridhara, R.; Chen, G.; McGuinn Jr, W.D.; Morse, D.; et al. United States Food and Drug Administration drug approval summary: gefitinib (ZD1839, Iressa) tablets. Clin. Cancer. Res., 2004, 10:1212-8
28. Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues Pereira, J.; Ciuleanu, T.; von Pawel, J.; et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung cancer). Lancet, 2005, 366:1527-37
29. Blackhall, F.; Ranson, M.; Thatcher, N. Where next for gefitinib in patients with lung cancer? Lancet Oncol., 2006, 7:499-507
30. Cufer, T.; Vrdoljak, E.; Gaafar, R.; Erensoy, I.; Pemberton, K.; SIGN Study Group. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs, 2006, 17:401-9
31. Kim, E.S.; Hirsh, V.; Mok, T.; Socinski, M.A.; Gervais, R.; Wu Y.L.; et al. Gefitinib versus docetaxel in previously treated non-smallcell lung cancer (INTEREST): a randomised phase III trial. Lancet, 2008, 372:1809-18
32. Douillard, J.Y.; Shepherd, F.A.; Hirsh, V.; et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J. Clin. Oncol., 2010, 28(5):744-752
33. Maruyama, R.; Nishiwaki, Y.; Tamura, T.; et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol., 2008, 26(26):4244-4252
34. Lee, D.H.; Park, K.; Kim, J.H.; et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clinical Cancer Research, 2010, 16(4):1307-1314
35. Shepherd, F.A.; Douillard, J.; Fukuoka, M.; et al. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): meta-analysis from four clinical trials. J. Clin. Oncol., 2009, 27(15, supplement) (abstract no. 8011)
36. Miller, V.A.; Johnson, D.H.; Krug, L.M.; et al: Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell-lung cancer. J. Clin. Oncol., 2004, 22:777-784
37. Giaccone, G.; Herbst, R.S.; Manegold, C.; Scagliotti, G.; Rosell, R.; Miller, V.; et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol., 2004, 22:777-84
38. Herbst, R.S.; Giaccone, G.; Schiller, J.H.; Natale, R.B.; Miller, V.; Manegold, C.; et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol., 2004, 22:785-94
39. Ciardiello, F.; Caputo, R.; Bianco, R.; et al: Antitumor effect and poyentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res., 2000, 6:2053-2063
40. Reck, M.; Buchholz, E.; Romer, K.S.; Krutzfeldt, K.; Gatzemeier, U.; Manegold, C. Gefi-tinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer. Clin. Lung Cancer, 2006, 7:406-11
41. Niho, S.; Kubota, K.; Goto, K.; Yoh, K.; Ohmatsu, H.; Kakinuma, R.; et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol., 2006, 24:64-9
42. Crinò, L.; Cappuzzo, F.; Zatloukal, P.; Reck, M.; Pesek, M.; Thompson, J.C.; et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J. Clin. Oncol., 2008, 26:4253-60
43. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; et al. Activating mutations in the epidermal growth factor receptor underly-ing responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, 350:2129-39
44. Paez, J.G.; Jänne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304:1497-500
45. Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; Sarkaria, I.; et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA, 2004, 101:13306-11
46. Rosell, R.; Moran, T.; Queralt, C.; Porta, R.; Cardenal, F.; Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med., 2009, 361:958-67
47. Costanzo, R.; Piccirillo, M. C.; Sandomenico, C.; Carillio, G.; Montanino, A.; Daniele, G.; Giordano, P.; Bryce, J.; De Feo, G.; Di Maio, M.; Rocco, G.; Normanno, N.; Perrone, F.; Morabito, A. Gefitinib in Non Small Cell Lung Cancer. Journal of Biomedicine and Biotechnology, vol 2011
48. Asahina, H.; Yamazaki, K.; Kinoshita, I.; Sukoh, N.; Harada, M.; Yokouchi, H.; et al. A phase II trial of gefitinib as first-line therapy for advanced nonsmall cell lung cancer with epidermal growth factor receptor mutations. Br. J. Cancer, 2006, 95:998-1004
49. Inoue, A.; Suzuki, T.; Fukuhara, T.; Maemondo, M.; Kimura, Y.; Morikawa, N.; et al. Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol., 2006, 24:3340-6
50. Yang, C.H.; Yu, C.J.; Shih, J.Y.; et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J. Clin. Oncol., 2008, 26(16):2745-2753
51. Sequist, L.V.; Martins, R.G.; Spigel, D.; Grunberg, S.M.; Spira, A.; Jänne, P.A.; et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol., 2008, 26:2442-9: J. Clin. Oncol. 26:3472
52. Sutani, A.; Nagai, Y.; Udagawa, K.; Uchida, Y.; Koyama, N.; Murayama, Y.; et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor recep-tor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br. J. Cancer., 2006, 95:1483-9
53. Yoshida, K.; Yatabe, Y.; Park, J.Y.; et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. Journal of Thoracic Oncology, 2007, 2(1):22-28
54. Sunaga, N.; Tomizawa, Y.; Yanagitani, N.; et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer, 2007, 56(3):383-389
55. Tamura, K.; Okamoto, I.; Kashii, T.; Negoro, S.; Hirashima, T.; Kudoh, S.; et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br. J. Cancer, 2008, 98: 907-14
56. Sugio, K.; Uramoto, H.; Onitsuka, T.; et al. Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer, 2009, 64(3):314-318
57. Inoue, A.; Kobayashi, K.; Usui, K.; et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J. Clin. Oncol., 2009, 27(9):1394-1400
58. Cappuzzo, F.; Ligorio, C.; Jänne, P.A.; Toschi, L.; Rossi, E.; Trisolini, R.; et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization positive/phospho-akt-positive or never smoker patients with advanced non-small-cell lung cancer: The ONCOBELL Trial. J. Clin. Oncol., 2007, 25:2248-55
59. West, H.L.; Franklin, W.A.; McCoy, J.; et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group study S0126. J. Clin. Oncol. 2006, 24(12):1807-1813
60. Lee, D.H.; Han, J.Y.; Yu, S.Y.; Kim, H.Y.; Nam, B.H.; Hong, E.K.; et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study. J. Thorac. Oncol., 2006, 1:965-71
61. Gridelli, C.; De Marinis, F., Di Maio, M.; Cortinovis, D.; Cappuzzo, F.; Mok, T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer, 2010
62. Mok, T.S., Wu, Y.L.; Thongprasert, S.; Yang, C.H.; Chu, D.T.; Saijo, N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med., 2009, 361:947-57
63. Lee, J.S.; Park, K.; Kim, S.W.; Lee, D.H.; Kim, H.T.; Han, J.Y.; et al.Presented at World Conference on Lung Cancer. A randomized phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung 2009, [abstractact PRS.4]
64. Mitsudomi, T.; Morita, S.; Yatabe, Y.; Negoro, S.; Okamoto, I.; Tsurutani, J.; et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol., 2010, 11: 121-8
65. Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; et al. Gefi tinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med., 2010, 362:2380-8
66. Fukuoka, M.; Wu, Y-L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S-S.; Sriuranpong, V.; Chao, T-Y.; Nakagawa, K.; Chu, D-T.; Saijo, N.; Duffield, E. L.; Rukazenkov, Y.; Speake, G.; Jiang, H.; Armour, A. A.; To, K-F.; Chih-Hsin Yang, J.; Mok, T. S. K. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS). J. Clin. Oncol., 2011, 29(21):2866-2874
67. Gaafar, R. M.; Surmont, V. F.; Scagliotti, G. V.; Van Klaveren, R. J.; Papamichael, D.; Welch, J. J.; Hasan, B.; Torri, V.; van Meerbeeck, J. P. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). European Journal of Cancer 47, 2011, 2331-2340
68. Li Zhang. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804). ASCO Annual Meeting 2011
69. Bria, E.; Milella, M.; Cuppone, F.; Novello, S.; Ceribelli, A.; Vaccaro, V., Sperduti, I.; Gelibter, A.; Scagliotti, G.V.; Cognetti, F.; Giannarelli, D. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann. Oncol., 2011 Oct, 22(10):2277-85. Epub 2011 Feb 16.
70. Moyer, J.D.; Barbacci, E.G.; Iwata, K.K. et al: Induction of apoptosis and cell cycle arrest by OSI-774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res., 1997, 57:4838-4848
71. Pollack, V.A.; Savage, D.M.; Baker, D.A.; et al. inhibition of epidermal growth factor receptor associated tyrosine phosphorylation in human carcinoma with OSI-774: dynamic of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther., 1999, 291:739-748
72. Sandler, A. Clinical experience with HER1/EGFR tyrosine kinase inhibitor erlotinib. Oncology, 2003, 17: 17-22
73. Perez-Soler, R.; Chachoua, A.; Huberman, M.; et al, Finals results of a Phase II study of erlotinib (Tarceva) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy (abstract P-611). Lung Cancer, 2003, 41(Suppl. 2): S246
74. Miller, V.A.; Patgel, J.; Shan, N.; et al. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): Preliminary results of a phase II trial. Proc. Am. Soc. Clin. Oncol., 2003, 22: 619 (abstr 2491)
75. Shepherd, F.A.; Pereira, J.R.; Ciuleanu, T.E.; et al. Erlotinib in previously treated non-small cell lung cancer. N. Eng. J. Med., 2005, 353: 123-132
76. Hamilton, M.; Wolf, J.L.; Rusk, J.; et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin. Cancer Res., 2005, 12:2166-2171
77. Tsao, M-S.; Sakurada, A.; Cutz, J-C; et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N. Engl. J. Med., 2005, 353:133-144
78. Herbst, R.S.; Prager, D.; Hermann, R.; Fehrenbacher, L.; Johnson, B.E.; Sandler, A.; et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol., 2005, 23: 5892-9
79. Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F.; et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol., 2007, 25: 1545-52
80. Gatzemeier, U.; Heller, A.; Foernzler, D.; Moecks, J.; de Rosa, F.; et al. Exploratory analyses EGFR, KRAS mutations and other molecular markers in tumors of NSCLC patients treated with chemotherapy +/-erlotinib (TALENT). J. Clin. Oncol., 2005, 23 6272, (suppl; abstr 7028)
81. Giaccone, G.; Gallegos Ruiz, M.; Le Chevalier, T.; Thatcher, N.; Smit, E.; Rodriguez, J.A.; et al. Erlotinib for frontline treatment of advanced Non-Small Cell Lung Cancer: a Phase II Study. Clin. Cancer Res., 2006, 2:6049-55
82. Jackman, D.M.; Yeap, B.Y.; Lindeman, N.I.; Fidias, P.; Rabin, M.S.; Temel, J.; et al. Phase II clinical trial of chemotherapy naïve patients > 70 years of age treated with erlotinib for advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol., 2007, 25:751-3
83. Jackman, D.; Pao, W.; Riely, G.J.; Engelman, J.A.; Kris, M.G.; Janne, P.A.; Lynch, T.; Johnson, B.E.; Miller, V.A. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol., 28:357-360
84. The elderly lung cancer vinorelbine Italian study group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J. Natl. Cancer Inst.,.1999, 91:66-72
85. Gridelli, C; Perrone, F.; Gallo, C; et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J. Natl. Cancer Inst., 2003, 95:362-372
86. Lilenbaum, R.; Herndon J.E. II; List, M.A.; et al. Single agent versus combination chemotherapy in advanced non-small cell lung cancer: the cancer and Leukemya group B (study 9730). J. Clin. Oncol., 2005, 23:190-196
87. Langer, C.J.; Manola, J.; Bernardo, P.; et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of eastern cooperative oncology group 5592, a randomized trial. J. Natl. Cancer Institute, 2002, 94: 173-181
88. Lilenbaum, R.; Axelrod, R.; Thomas, S.; Dowlati, A.; Seigel, L.; Albert, D.; Witt, K.; Botkin, D. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced Non-Small cell lung cancer and Performance status of 2. J. Clin. Oncol., 2008 Feb, 20;26(6):863-9
89. Shan, N.T.; Kris, M.G.; Pao, W.; et al. Practical management of patients with non-small cell lung cancer treated woth gefitinib. J. Clin. Oncol., 2005, 23: 165-174
90. Gridelli, C; Ciardiello, F.; Feld, R.; Butts, CA; Gebbia, V.; Genestreti, G.; et al. International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial.[abstract]. J. Clin. Oncol., 2010, 28: 7508
91. Lee, S.; Rudd, R.; Khan, I.; Upadhyay, S.; Lewanski, CR.; Falk, S.; et al. TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy[abstract]. J. Clin. Oncol., 2010, 28: 7504
92. Zhou, C; Wu, Y.L.; Chen, G.; Feng, J.; Liu, X.; Wang, C; et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in chinese advanced non-small-cell lung cancer patients with EGFR activating mutations [abstract]. Ann. Oncol., 2010, 21: LBA13
93. Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Palmero, R.; Garcia-Gomez, R.; Pallares, C; Sanchez, J. M.; Porta, R.; Cobo, M.; Garrido, P., Longo, F.; Moran, T.; Insa, A.; De Marinis, F.; et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol., 2012, 13: 239-46
94. Pohlmann, P.R.; Mayer, I.A.; Mernaugh, R. Resistance to trastuzumab in breast cancer. Clin. Cancer Res., 2009, 15:7479-91
95. Greulich, H.; Chen, T.H.; Feng, W.; et al. Oncogenic transformation by inibitor-sensitive and resistant EGFR mutants. PLoS. Med., 2006, 2:e313
96. Wang, S.E.; Narasanna, A.; Perez-Torres, M.; et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell, 2006, 10:25-38
97. Pao, W.; Wang, T.Y; Riely, G.J.; et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoSMed., 2005, 2:e17
98. Tam, I.Y; Chung, L.P.; Suen, W.S.; et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin. Cancer Res., 2006, 12:1647-1653
99. Eberhard, D.A.; Johnson, B.E., Amler, L.C; et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol., 2005, 23:5900-5909
100. Shaw, A.T., Yeap, B.Y, Mino-Kenudson, M., Digumarthy, S.R., Costa, D.B., Heist, R.S. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol., 27: 424-4253
101. Ellis, L.M.; Hicklin, D.J. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin. Cancer Res., 2009, 15:7471-8
102. Kobayashi, S.; Boggon, T.J.; Dayaram, T.; et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2005, 352: 786-92
103. Pao, W.; Miller, V.A.; Politi, K.A.; et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS. Med., 2005, 2:e73
104. Yun, C.H.; Mengwasser, K.E.; Toms, A.V.; et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U S A., 2008, 105:2070-5
105. Bean, J.; Riely, G.J.; Balak, M.; et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin. Cancer Res., 2008, 14:7519-25
106. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007, 316:1039-43
107. Yano S.; Wang W.; Li Q.I.; et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Research, 2008, vol. 68, no. 22, pp. 9479-9487
108. Yang, C; Shih, J.; Su, W.; et al. A Phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUXLung 2). Abstract Presented at the European Society of Medical Oncology (ESMO) Congress, 2010 October, abstract 367PD
109. Miller, V.A.; Hirsch, V.; Cadranel, J.; et al. Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 b best supportive care (BSC) versus placebo b BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1). Proceedings of European Society of Medical Oncology (ESMO) Congress, 2010 October, abstract LBA1
110. Zhuang, H.Q.; Wang, J.; Yuan, Z.Y; Zhao, L.J.; Wang, P.; Wang, CL. The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro. J. Exp. Clin. Cancer Res., 2009 Sep, 1;28:123
111. Provencio, M.; Sánchez, A.; Garrido, P.; Valcárcel, F. New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin. Lung Cancer, 2010 Mar, 1;11(2):91-7
112. Chang, C.C.; Chi, K.H.; Kao, S.J.; Hsu, P.S.; Tsang, Y.W.; Chang, H.J.; Yeh, Y.W.; Hsieh, Y.S.; Jiang, J.S. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung Cancer, 2011 Aug, 73(2):189-9
113. Niho, S., Ohe, Y.; Ishikura, S.; Atagi, S.; Yokoyama, A.; Ichinose, Y.; Okamoto, H.; Takeda, K.; Shibata, T.; Tamura, T.; Saijo, N.; Fukuoka, M. Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402). Ann. Oncol., 2012 Feb, 22
114. Langer, C.J. The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J. Clin. Oncol., 2009, 27:1350-4
115. Suzumura, T.; Kudoh, S.; Kimura, T.; et al. Comparison of adverse events of erlotinib with dose of gefitinib in Japanese patients with NSCLC. J. Clin. Oncol., 2010, 28 (Suppl):15s, abstract 7566